North America Hepatitis B Treatment Market worth $3.01 billion by 2033 - Exclusive Report by DatamIntelligence

"The North America hepatitis B treatment market reached US$ 1.66 billion in 2024 and is expected to reach US$ 3.01 billion by 2033, growing at a CAGR of 6.9% during the forecast period 2025-2033." As per DataM intelligence research report

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/north-america-hepatitis-b-treatment-market?sp

United States: Recent Industry Developments

✅ In January 2025, Durham-based biotech firm Tune Therapeutics raised $175 million to fund clinical trials of its gene tuning treatment aimed at chronic hepatitis B. The therapy works by tweaking gene expression to neutralize the virus, potentially offering a significant breakthrough in epigenetic control for virus prevention.

✅ In November 2024, the U.S. Food and Drug Administration (FDA) approved Bulevirtide (Hepcludex) for the treatment of chronic hepatitis D in the presence of hepatitis B. This approval marks a significant advancement in the management of co-infected patients.

✅ In October 2024, the American Association for the Study of Liver Diseases (AASLD) released updated guidelines emphasizing the importance of early antiviral therapy initiation in patients with chronic hepatitis B, even in the absence of elevated alanine aminotransferase (ALT) levels, to prevent progression to cirrhosis and hepatocellular carcinoma.

✅ In September 2024, a study published in the Journal of Hepatology highlighted the potential of combination therapies, including pegylated interferon and nucleos(t)ide analogs, in achieving sustained hepatitis B surface antigen (HBsAg) loss, suggesting a shift towards functional cure strategies.

Canada: Recent Industry Developments

✅ In August 2025, Health Canada approved Bulevirtide (Hepcludex) for the treatment of chronic hepatitis D in the presence of hepatitis B, expanding therapeutic options for co-infected patients.

✅ In July 2025, the Canadian Association for the Study of the Liver (CASL) updated its guidelines, recommending tenofovir alafenamide (TAF) as a first-line treatment for chronic hepatitis B, citing its improved safety profile compared to tenofovir disoproxil fumarate (TDF).

✅ In June 2025, a Canadian study published in the Canadian Liver Journal reported that early initiation of antiviral therapy in patients with chronic hepatitis B led to a significant reduction in liver-related complications and improved long-term outcomes.

✅ In May 2025, the Canadian Liver Foundation launched a national awareness campaign aimed at increasing hepatitis B screening rates, particularly among high-risk populations, to promote early detection and treatment.

North America Hepatitis B Treatment Market: Drivers

The North America hepatitis B treatment market is witnessing steady growth, driven by rising prevalence of chronic hepatitis B infections, increasing awareness about liver diseases, and growing demand for effective antiviral therapies. Hepatitis B, a viral infection affecting the liver, can lead to serious complications such as cirrhosis, liver failure, and hepatocellular carcinoma, creating a strong need for early diagnosis and long-term treatment options. Advances in antiviral therapies, including nucleos(t)ide analogs and interferon-based treatments, are improving viral suppression, disease management, and patient outcomes. Expansion of liver disease screening programs, patient awareness campaigns, and healthcare infrastructure is further supporting market adoption. Increasing focus on preventive care, early intervention, and personalized treatment strategies is boosting demand for hepatitis B therapeutics in the region.

Leading pharmaceutical companies, including Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, and Merck, are actively developing innovative therapies for hepatitis B, focusing on long-acting antivirals, combination therapies, and improved safety profiles. Research into novel therapeutic agents, immunomodulators, and potential curative treatments is expanding the treatment landscape. Strategic collaborations between pharma companies, healthcare providers, and research institutions are accelerating clinical development, regulatory approvals, and commercialization of new therapies. Growing focus on chronic disease management, liver health awareness, and patient-centric care is driving adoption. With continuous innovation, increasing disease prevalence, and expanding access to antiviral therapies, the North America hepatitis B treatment market is poised for sustained growth.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/north-america-hepatitis-b-treatment-market?sp

North America Hepatitis B Treatment Market: Major Players

Gilead Sciences, Dynavax Technologies Corporation, GSK Plc, Merck & Co. Inc., Sanofi, Apotex Inc., VBI Vaccines Inc., Bristol-Myers Squibb Company, and Viatris Inc., among others.

Segment Covered in the North America Hepatitis B Treatment Market:

➥ By Type: Chronic, Acute

➥ By Treatment: Vaccines, Antiviral Drugs, Immuno Modulator Drugs

➥ By Route of Administration: Parenteral, Oral

➥ By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Research Process:

Both primary and secondary data sources have been used in the North America Hepatitis B Treatment Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Most Frequently Asked Questions in the North America Hepatitis B Treatment Market Research Industry:

➠ Who leads the North America Hepatitis B Treatment industry and what's their competitive positioning regarding capacity, performance, and profitability?
➠ What growth opportunities and market challenges do North America Hepatitis B Treatment market vendors face?
➠ Which segments show the highest growth potential and market share distribution?
➠ What factors are driving or limiting North America Hepatitis B Treatment market growth?
➠ What are the dominant sales and distribution strategies in the North America Hepatitis B Treatment industry?

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=north-america-hepatitis-b-treatment-market

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sp

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.